As presented in Fig 2A, KS-133 alone tended to suppress CT26 tumor growth, whereas KS-133 displayed significant and additive anti-tumor effects in combination with an anti-PD-1 antibody (p < 0.001). The gene discussed is PDCD1; the disease is neoplasm.